Who are AMG 853's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tivdak, Tisotumab Vedotin, Hympavzi, Eptacog alfa (NovoSeven), BT595, BIVV009.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amg-853.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

AMG 853 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AMG 853 (AMG 853) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tissue factor inhibitor. Area: Cardiovascular.

phase 2 Tissue factor inhibitor Tissue factor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

AMG 853 (AMG 853) — Amgen. AMG 853 is a recombinant, humanized monoclonal antibody that targets and neutralizes tissue factor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AMG 853 TARGET	AMG 853	Amgen	phase 2	Tissue factor inhibitor	Tissue factor
Tivdak	tisotumab-vedotin	SEAGEN	marketed	Antibody-drug conjugate	Tissue factor	2021-01-01
Tisotumab Vedotin	tivdak	SEAGEN	marketed	Antibody-Drug Conjugate (ADC)	Tissue factor	2021-01-01
Hympavzi	Marstacimab-Hncq	Pfizer Inc.	marketed	Tissue Factor Pathway Inhibitor (TFPI) Antagonist	Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)
Eptacog alfa (NovoSeven)	Eptacog alfa (NovoSeven)	Novo Nordisk A/S	marketed	Recombinant coagulation factor	Tissue factor (TF) / Factor X
BT595	BT595	Biotest	phase 3	Monoclonal antibody (anti-TFPI)	Tissue Factor Pathway Inhibitor (TFPI)
BIVV009	BIVV009	Bioverativ, a Sanofi company	phase 3	TFPI inhibitor monoclonal antibody	Tissue Factor Pathway Inhibitor (TFPI)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tissue factor inhibitor class)

Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AMG 853 — Competitive Intelligence Brief. https://druglandscape.com/ci/amg-853. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing